US court denies Wyeth bid to halt Zosyn generic-India's Orchid

MUMBAI, Sept 24 (Reuters) - India's Orchid Chemicals ORCD.BO said on Thursday a U.S. court had denied Wyeth's WYE.N motion for a temporary restraining order on the sale of its generic version of the Zosyn antibiotic.

Late on Wednesday, Wyeth filed a suit against the U.S. Food and Drug Administration (FDA) in the U.S. District Court for the District of Columbia, claiming the agency’s approval of Orchid’s version of its blockbuster Zosyn endangered patient health. [ID:nN23399659]

Wyeth said the FDA’s approval of Orchid’s generic version was unlawful and requested a temporary restraining order or an injunction ordering the agency to withdraw or suspend its approval of Orchid’s application.

“We understand that the matter has since been heard briefly by the Court. Based on a minute note filed in the court’s dockets late on Wednesday, the Court has determined that it would issue a written memorandum opinion denying Wyeth’s motion for a temporary restraining order,” Orchid said in a statement.

Earlier this month, Orchid Chemicals & Pharmaceuticals Ltd won approval to sell its generic version of Zosyn, chemically piperacillin-tazobactam, with a 180-day marketing exclusivity.

“Wyeth will do what it has to do and we will do what we have to do,” Orchid’s managing director, Raghavendra Rao, told Reuters. “We have already started distributing the drug in partnership with Apotex. We will continue to do the same.”

Orchid shares, which fell as much as 2.7 percent in the session, were down 1.6 percent at 162.70 rupees in a Mumbai market down 0.3 percent at 0914 GMT. (Reporting by Bharghavi Nagaraju; Editing by Lincoln Feast)